These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 9816021)

  • 1. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
    Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
    Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
    Tamura T; Sasaki Y; Nishiwaki Y; Saijo N
    Jpn J Cancer Res; 1995 Dec; 86(12):1203-9. PubMed ID: 8636011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.
    Maier-Lenz H; Hauns B; Haering B; Koetting J; Mross K; Unger C; Bauknecht T; du Bois A; Meerpohl HG; Hollaender N; Diergarten K
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-16-S19-19. PubMed ID: 9427259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
    Doz F; Gentet JC; Pein F; Frappaz D; Chastagner P; Moretti S; Vassal G; Arditti J; Tellingen OV; Iliadis A; Catalin J
    Br J Cancer; 2001 Mar; 84(5):604-10. PubMed ID: 11237379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
    Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
    Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer.
    Sekine I; Nishiwaki Y; Watanabe K; Yoneda S; Saijo N
    Clin Cancer Res; 1996 Jun; 2(6):941-5. PubMed ID: 9816254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
    Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
    Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
    Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
    Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
    Soepenberg O; Sparreboom A; de Jonge MJ; Planting AS; de Heus G; Loos WJ; Hartman CM; Bowden C; Verweij J
    Eur J Cancer; 2004 Mar; 40(5):681-8. PubMed ID: 15010068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
    Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
    Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
    Karlsson MO; Molnar V; Bergh J; Freijs A; Larsson R
    Clin Pharmacol Ther; 1998 Jan; 63(1):11-25. PubMed ID: 9465838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect-response model for the time course of leukopenia with anticancer drugs.
    Minami H; Sasaki Y; Saijo N; Ohtsu T; Fujii H; Igarashi T; Itoh K
    Clin Pharmacol Ther; 1998 Nov; 64(5):511-21. PubMed ID: 9834043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
    Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
    Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
    Boddy AV; Plummer ER; Todd R; Sludden J; Griffin M; Robson L; Cassidy J; Bissett D; Bernareggi A; Verrill MW; Calvert AH
    Clin Cancer Res; 2005 Nov; 11(21):7834-40. PubMed ID: 16278406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
    Mita AC; Olszanski AJ; Walovitch RC; Perez RP; MacKay K; Tuck DP; Simmons C; Hammond S; Mita MM; Beeram M; Stone AJ; Rowinsky EK; Lewis LD
    Clin Cancer Res; 2007 Jun; 13(11):3293-301. PubMed ID: 17545535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on hypersensitivity and pharmacokinetics of paclitaxel microemulsion].
    He L; Wang GL; Zhang Q
    Yao Xue Xue Bao; 2003 Mar; 38(3):227-30. PubMed ID: 12830723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.